NFKB1 and acute myeloid leukemia: Accordingly, NF-κB inhibition reduces LIN28B expression and cell survival as well as LSCs’ self-renewal in vitro, suggesting that inhibition of NF-κB could be a potential opportunity to kill AML cells and LSCs in order to counteract cancer resistance and disease relapse [29].